Candida auris

Invasive Aspergillosis Drug Pipeline Report 2022: Comprehensive Insights on Active Companies and Pipeline Drugs Featuring F2G, SCYNEXIS, Pulmocide, & TFF Pharmaceuticals - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 20, 2022
Health, Pharmaceutical, Aspergillosis, Clinical trial, MDR, European Medicines Agency, QIDP, Breakthrough therapy, Research, III, News, NDA, Candida auris, Auris, Disease, Acquisition, Discovery, Infection, Drug of last resort, FDA, Therapy, Goodyear F2G Corsair, II, IV, Pharmaceutical industry, Aspergillus, Pneumocystidomycetes

This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Invasive Aspergillosis pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Invasive Aspergillosis pipeline landscape.
  • The assessment part of the report embraces, in depth Invasive Aspergillosis commercial assessment and clinical assessment of the pipeline products under development.
  • This segment of the Invasive Aspergillosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Invasive Aspergillosis R&D.

SCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant Fungi

Retrieved on: 
Wednesday, November 30, 2022
Pathology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Tablet, Echinocandin, Polyene, Skin, Dermatology, Mycology, Fluconazole, WHO, CDC, Auris, Infection, Food, Medical Mycology, University Hospital Medical Center at Treichville, Shanda, Icahn School of Medicine at Mount Sinai, National Institute of Allergy and Infectious Diseases, Biotechnology, Candida auris, Patient, Mortality, QIDP, Candidiasis, FLU, World Health Organization, Case Western Reserve University, University Hospitals Cleveland Medical Center, Centers for Disease Control and Prevention timeline, School, NIH, Research, Fungus, Encephalitis, Azole, IV, Drug of last resort, New Drug Application, PDUFA, FDA, Pharmaceutical industry, Vaccine

We congratulate Dr. Ghannoum on receiving this grant and want to express our gratitude for his ongoing commitment to patients suffering from terrible and deadly fungal infections.

Key Points: 
  • We congratulate Dr. Ghannoum on receiving this grant and want to express our gratitude for his ongoing commitment to patients suffering from terrible and deadly fungal infections.
  • C. auris has emerged in recent years as a global threat causing serious invasive infections with mortality as high as 60 percent worldwide.
  • The World Health Organization (WHO) recently released its first ever fungal priority pathogens list (FPPL), which includes C. auris in the critical priority group.
  • In addition, late-stage clinical investigation of ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing.

SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats

Retrieved on: 
Thursday, November 17, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Tablet, Shanda, Mycosis, European Medicines Agency, WHO, Public health, Auris, Infection, Food, Biomedical Advanced Research and Development Authority, IC, EMA, IA, Biotechnology, BAA, Candida auris, Patient, QIDP, Candidiasis, Broad Agency Announcement, Aspergillus fumigatus, FURI, World Health Organization, Mucorales, News, BID, Fungemia, Fungus, Development, CBRN, Canker, IV, Drug of last resort, New Drug Application, MCM, PDUFA, FDA, Antibiotics, Pharmaceutical industry

For the first time, BARDA announced this week it is seeking partnerships to develop broad-spectrum next-generation antifungal drugs to treat high-priority fungal infections.

Key Points: 
  • For the first time, BARDA announced this week it is seeking partnerships to develop broad-spectrum next-generation antifungal drugs to treat high-priority fungal infections.
  • It is extremely exciting to see BARDA announce increased emphasis on fighting dangerous fungal pathogens, said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS.
  • Ibrexafungerp, with its promising activity against multiple drug resistant and often-deadly fungal infections, has enormous potential to benefit patients with severe fungal disease and limited treatment options.
  • In addition, late-stage clinical investigation of oral ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing.

SCYNEXIS Provides Corporate, Commercial and R&D Strategy Updates to Expand Market Potential for Its First-in-Class Antifungal

Retrieved on: 
Thursday, October 20, 2022
CFO, Candida auris, Growth, Candidiasis, NASDAQ, Patient, Biotechnology, IV, Auris, Partnership, FURI, VVC, Company, Industry, PBM, Board, CEO, Mycosis, EDT, GLOBE, Director, Drug of last resort, Tablet, Prescription, Leadership, Pharmaceutical industry, Airline, Management, Perfume

During this process, SCYNEXIS will wind down its promotional activities, while keeping BREXAFEMME on the market and available to patients.

Key Points: 
  • During this process, SCYNEXIS will wind down its promotional activities, while keeping BREXAFEMME on the market and available to patients.
  • SCYNEXIS will conclude the partnership with its contracted commercial sales partner, Amplity Health, and will undertake a workforce reduction.
  • SCYNEXIS is announcing changes to its executive leadership team:
    Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will retire as of December 31, 2022.
  • During this process, SCYNEXIS will wind down its promotional activities, while keeping BREXAFEMME on the market and available to patients.

SCYNEXIS Presents Positive Interim Data of Ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study During the Mycoses Study Group Education and Research Consortium (MSGERC) Biennial Meeting

Retrieved on: 
Thursday, September 8, 2022
European Medicines Agency, Mortality, Patient, HIV disease progression rates, EMA, Fungemia, Tablet, System Infected: Backdoor VBS Dunihi, VVC, IA, Medical Affairs Bureau, NASDAQ, IV, Candidiasis, Disease, Death, QIDP, PDUFA, New Drug Application, Food, Candida auris, Infection, Mycosis, GLOBE, FDA, Biotechnology, Auris, IC, FURI, Drug of last resort, Shanda, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry

Data from the ongoing Phase 3 CARES study will also be presented demonstrating positive outcomes of ibrexafungerp in 89% of patients with Candida auris, complete/partial response (78%) and no disease progression (11%).

Key Points: 
  • Data from the ongoing Phase 3 CARES study will also be presented demonstrating positive outcomes of ibrexafungerp in 89% of patients with Candida auris, complete/partial response (78%) and no disease progression (11%).
  • The new interim analyses are being presented during the Mycoses Study Group Education and Research Consortium (MSGERC) Biennial Meeting being held in Albuquerque, N.M., September 7-9, 2022.
  • The interim analysis included 64 patients from the FURI study with refractory Candida infections, including failure of or resistance to previous standard-of-care antifungal therapy.
  • In addition, late-stage clinical investigation of oral ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing.

SCYNEXIS Reports First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 12, 2022
Infection, Auris, Company, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Survival, EDT, Posaconazole, POSA, Candida auris, Fluconazole, Patient, NASDAQ, Drug of last resort, European, IV, Prescription, Data, BID, FDA, Mycosis, Mouse, Recurrence, Commercial, Biotechnology, FURI, Congress, NDA, LAMB, Tablet, Candidiasis, Headache, Mucormycosis, Fungemia, HCPS, GLOBE, Pharmaceutical industry, Insurance, Medical device, IQVIA, VVC

SCYNEXIS will host a conference call today, May 12 at 8:30 a.m. EDT

Key Points: 
  • SCYNEXIS will host a conference call today, May 12 at 8:30 a.m. EDT
    JERSEY CITY, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the first quarter ended on March 31, 2022.
  • Research and development expense for the first quarter of 2022 decreased to $5.7 million from $6.9 million versus the first quarter of 2021.
  • Selling, general & administrative (SG&A) expense for the first quarter of 2022 increased to $14.6 million from $6.7 million versus the first quarter of 2021.
  • Total other income was $9.6 million for the first quarter of 2022, versus total other expense of $2.0 million for the first quarter of 2021.

Southgate Community Schools Enlists Germ-Zapping Robot to Battle Coronavirus

Retrieved on: 
Thursday, May 5, 2022
Automotive, Technology, General Health, Other Health, Mobile, Wireless, Consumer, Preschool, Construction & Property, Infectious Diseases, Security, Other Technology, Other Education, University, Software, Health, Primary, Secondary, Education, Internet, Other Consumer, Hardware, COVID-19, Airport, Staphylococcus, Disinfectant, Student, Prison, Southgate, University, Mercury, Light-emitting diode, Southgate Community School District, Health, Safety, Deactivation, School, Patient, K-12, Virus, Secondary and Higher Education Division, Superintendent, Infection, Candida auris, Creativity, Partnership, Methicillin, Norovirus, Hospital, Staphylococcus aureus, Government, Frost & Sullivan, Learning, Severe acute respiratory syndrome coronavirus 2, MRSA, Education, Battery Ventures, Solution, Bacteria, Growth, Multimedia, Vaccine, Forefront, COVID, UV

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    Southgate Community Schools recently partnered with Forefront to provide comprehensive custodial services for the districts eight schools.
  • Forefront began providing custodial services for Southgate Community Schools in March 2022.
  • Southgate Community Schools invested in Forefront, an environmental services company with an established industry background in healthcare infection prevention.
  • Using the LightStrike robot and Deactivate devices at Southgate Community Schools Fordline Elementary campus enabled us to quickly destroy germs that we cant see, but that could potentially be transmitted to a person, said Forefront CEO & Co-Founder, Dan Bowen.

SCYNEXIS Presents Data Analyses Showing Ibrexafungerp’s Potential to Fight Invasive Candidiasis and Candidemia, Including Infections Caused by Candida Auris, During the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases

Retrieved on: 
Wednesday, April 27, 2022
Patient, Treatment, Biotechnology, COVID-19, Mucormycosis, NASDAQ, Research, European, Infection, LAMB, GLOBE, POSA, Drug of last resort, Mortality, Congress, FURI, Candida auris, Fungemia, Auris, HIV disease progression rates, Disease, Posaconazole, Mycosis, Interim, Survival, Pharmaceutical industry, Medical imaging

The posters were presented at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) held in Lisbon, Portugal April 23-26, 2022.

Key Points: 
  • The posters were presented at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) held in Lisbon, Portugal April 23-26, 2022.
  • We are excited to share these latest data with the medical community as we advance our hospital clinical programs in invasive candidiasis, including candidemia, said David Angulo, M.D.
  • Ibrexafungerp is in late-stage investigation and development for multiple indications, including life-threatening fungal infections caused primarily by Candida (including C. auris) and Aspergillus species in hospitalized patients.
  • In addition, late-stage clinical investigation of oral ibrexafungerp for the prevention of recurrent vulvovaginal candidiasis (VVC) and the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing.

PDI HEALTHCARE INTRODUCES NOVEL DISINFECTANTS TO BETTER PROTECT HEALTHCARE ENVIRONMENTS DURING CRITICAL TIME

Retrieved on: 
Tuesday, March 8, 2022
Risk, Subclinical infection, Infection, Infectious Diseases Society of America, ESKAPE, Patient, Klebsiella pneumoniae, Staphylococcus aureus, Hospital, Research, PDI, HAI, Korea Disease Control and Prevention Agency, Norovirus, Methicillin, Clostridioides difficile (bacteria), The New England Journal of Medicine, Enterobacteriaceae, Solution, Multistable perception, Disinfectant, Acinetobacter baumannii, COVID-19, Candida auris, Vancomycin, Klebsiella aerogenes, New Delhi metallo-beta-lactamase 1, Clostridioides, Environment, Enterobacter, Hydrogen peroxide, CDC, MDR, VRE, EPA, Health, Center, Severe acute respiratory syndrome coronavirus 2, CAD, Pseudomonas aeruginosa, No, MRSA, Pharmaceutical industry, Sewage, Eyeish

"Given PDI's long legacy of pioneering important infection prevention solutions, we are proud to offer healthcare facilities a solution that protects surfaces and equipment from recontamination around the clock."

Key Points: 
  • "Given PDI's long legacy of pioneering important infection prevention solutions, we are proud to offer healthcare facilities a solution that protects surfaces and equipment from recontamination around the clock."
  • "Today's vulnerable healthcare environment has prompted an urgent need to strengthen infection prevention programs to better safeguard patients and staff," said Watts.
  • "Multiple layers of defense, including effective and easy-to-use disinfectants, will continue to be key to helping prevent infections, save costs, and improve care."
  • PDI has three divisions, PDI Healthcare, Sani Professional and PDI Contract Manufacturing.

Matinas BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

Retrieved on: 
Tuesday, March 8, 2022
Form 10-K, Cryptococcosis, Allergy, Enrollment, LNC, Cohort, Infection, Nucleic acid, Degenerative disease, University of North Carolina at Greensboro, Science, Chapel Hill, Cystic fibrosis, Partnership, Auris, Private Securities Litigation Reform Act, Vaccine, Necessity and sufficiency, Forward-looking statement, Organic acid, European Medicines Agency, FDA, Solution, SEC, Company, Consultant, National Institute, Clinical trial, NTM, Enactment, EPA, Candida auris, Department, Investor, Food, NIAID, EMA, Hand, NYSE, Cystic Fibrosis Foundation, Sale, Mucormycosis, Risk, Technology, Asos, RNA transfection, Mycosis, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Research, DNA, Safety, University, UNC, Conference, SAD, DPA, DSMB, GLOBE, Therapy, Pharmaceutical industry

Preclinical studies of MAT2203 in Candida auris and mucormycosis (black fungus) scheduled to begin in the second quarter of 2022 to support potential label expansion.

Key Points: 
  • Preclinical studies of MAT2203 in Candida auris and mucormycosis (black fungus) scheduled to begin in the second quarter of 2022 to support potential label expansion.
  • Cash, cash equivalents and marketable securities at December 31, 2021, were approximately $49.6 million, compared to $58.7 million at December 31, 2020.
  • With the support of the Cystic Fibrosis Foundation, MAT2501 is currently undergoing important preclinical studies and commenced a Phase 1 human clinical trial in the fourth quarter of 2021.
  • Matinas BioPharmas product candidates are all in a development stage and are not available for sale or use.